Answers are grounded in this paper and cite their sources.
The persistence of emerging organic pollutants (EOPs) in the aquatic environment necessitates the development of selective and efficient treatment technologies. Peroxymonosulfate (PMS)-based advanced oxidation processes are promising, particularly when catalyzed by earth-abundant iron, which can generate high-valent FeIV=O, a selective oxidant with a long lifetime and high steady-state concentration. However, iron phthalocyanine (FePc), which mimics bioactive Fe–N4 sites, suffers from limited active site exposure and low stability due to dense intermolecular packing. In this work, we address these challenges by thermally embedding FePc nanocrystals into a polymeric carbon nitride (CN) framework. This process expands the interlayer spacing and increases the dimension of the crystal cell, but compresses the Fe–N bonds, and thereby significantly enhances both catalytic activity and stability. The optimized catalyst of FePc@CN-2 could efficiently activate PMS and degrade a series of antibiotics. Specifically, for ofloxacin degradation, FePc@CN-2 exhibited a remarkable catalytic activity of more than 100 times greater than that of the control catalyst (FePc@CN-0). Furthermore, the composite demonstrated exceptional long-term stability in a continuous-flow system, operating for over 2100 h at a flow rate of 0.4 mL min−1 with >95% ciprofloxacin. Mechanistic studies substantiated that high-valent FeIV=O was the predominant reactive species. This work presents a unique structural-engineering strategy to unlock the potential of FePc catalysis, offering a robust and highly efficient catalyst for selective pollutant degradation.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: